Literature DB >> 16242073

Nanoparticles for the optical imaging of tumor E-selectin.

Martin Funovics1, Xavier Montet, Fred Reynolds, Ralph Weissleder, Lee Josephson.   

Abstract

We designed a fluorescent peptide-magnetic nanoparticle conjugate that images E-selectin expression in mouse xenograft models of Lewis lung carcinoma (LLC) by fluorescence reflectance imaging. It was synthesized by attaching the E-selectin-binding peptide (ESBP; CDSDSDITWDQLWDLMK) to a CLIO(Cy5.5) nanoparticle to yield ESBP-CLIO(Cy5.5). Internalization by activated human umbilical vein endothelial cells (HUVECs) was rapid and mediated by E-selectin, indicated by the lack of uptake of nanoparticles bearing similar numbers of a scrambled peptide (Scram). To demonstrate the specificity of E-selectin targeting to ESBP-CLIO(Cy5.5) in vivo, we coinjected ESBP-CLIO(Cy5.5) and Scram-CLIO(Cy3.5) and demonstrated a high Cy5.5/Cy3.5 fluorescence ratio using the LLC. Histology showed that ESBP-CLIO was associated with tumor cells as well as endothelial cells, but fluorescence-activated cell sorter analysis showed a far less expression of E-selectin on LLC than on HUVECs. Using immunohistochemistry, we demonstrated E-selectin expression in both endothelial cells and cancer cells in human prostate cancer specimens. We conclude that ESBP-CLIO(Cy5.5) is a useful probe for imaging E-selectin associated with the LLC tumor, and that E-selectin is expressed not only on endothelial cells but also on LLC cells and human prostate cancer specimens.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16242073     DOI: 10.1593/neo.05352

Source DB:  PubMed          Journal:  Neoplasia        ISSN: 1476-5586            Impact factor:   5.715


  24 in total

Review 1.  A review of the past, present, and future directions of neoplasia.

Authors:  Alnawaz Rehemtulla; Brian D Ross
Journal:  Neoplasia       Date:  2005-12       Impact factor: 5.715

2.  In vivo imaging of molecularly targeted phage.

Authors:  Kimberly A Kelly; Peter Waterman; Ralph Weissleder
Journal:  Neoplasia       Date:  2006-12       Impact factor: 5.715

Review 3.  [Optical imaging of fluorescence in the near infrared. From passive to enzymatically activated contrast medium].

Authors:  M Funovics
Journal:  Radiologe       Date:  2007-01       Impact factor: 0.635

Review 4.  MR-optical imaging of cardiovascular molecular targets.

Authors:  Matthias Nahrendorf; David E Sosnovik; Ralph Weissleder
Journal:  Basic Res Cardiol       Date:  2008-03       Impact factor: 17.165

5.  Molecular imaging by micro-CT: specific E-selectin imaging.

Authors:  Caroline Wyss; Stephan C Schaefer; Lucienne Juillerat-Jeanneret; Lucienne Lagopoulos; Hans-Anton Lehr; Christoph D Becker; Xavier Montet
Journal:  Eur Radiol       Date:  2009-05-14       Impact factor: 5.315

6.  Breast Cancer Treatment in the Era of Molecular Imaging.

Authors:  Gundula Edelhauser; Martin Funovics
Journal:  Breast Care (Basel)       Date:  2008-12-17       Impact factor: 2.860

Review 7.  Multifunctional magnetic nanoparticles for targeted imaging and therapy.

Authors:  Jason R McCarthy; Ralph Weissleder
Journal:  Adv Drug Deliv Rev       Date:  2008-04-10       Impact factor: 15.470

8.  GGAP2/PIKE-a directly activates both the Akt and nuclear factor-kappaB pathways and promotes prostate cancer progression.

Authors:  Yi Cai; Jianghua Wang; Rile Li; Gustavo Ayala; Michael Ittmann; Mingyao Liu
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

9.  Manufacture of IRDye800CW-coupled Fe3O4 nanoparticles and their applications in cell labeling and in vivo imaging.

Authors:  Yong Hou; Yingxun Liu; Zhongping Chen; Ning Gu; Jinke Wang
Journal:  J Nanobiotechnology       Date:  2010-10-29       Impact factor: 10.435

10.  Identification of thioaptamer ligand against E-selectin: potential application for inflamed vasculature targeting.

Authors:  Aman P Mann; Anoma Somasunderam; René Nieves-Alicea; Xin Li; Austin Hu; Anil K Sood; Mauro Ferrari; David G Gorenstein; Takemi Tanaka
Journal:  PLoS One       Date:  2010-09-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.